On the Horizon
Over the coming year, Health Canada may approve several promising new drugs. These innovations will offer better treatment options for a range of diseases and help improve patients’ quality of life. However, the arrival of new formulations will bring significant changes to the pharmaceutical landscape.
We are seeing the introduction of treatments that are simpler to use and easier to administer, as well as drugs that work differently and more effectively. These advances often come with higher costs due to more complex clinical development steps, advanced technologies, or because of the greater medical value they provide.
Since many treatments are still under review at Desjardins Insurances, economic and clinical effectiveness analyses will be required to determine their eligibility for coverage. These evaluations will help identify the most appropriate cost‑control measures for these drugs; for example, whether they should be subject to a Product Listing Agreement (PLA), be part of the prior authorization drug program, or be included in the step therapy program.
The following is an overview of the key areas our team of specialists will be closely monitoring over the coming months.
Over the coming year, Health Canada may approve several promising new drugs. These innovations will offer better treatment options for a range of diseases and help improve patients’ quality of life. However, the arrival of new formulations will bring significant changes to the pharmaceutical landscape.
We are seeing the introduction of treatments that are simpler to use and easier to administer, as well as drugs that work differently and more effectively. These advances often come with higher costs due to more complex clinical development steps, advanced technologies, or because of the greater medical value they provide.
Since many treatments are still under review at Desjardins Insurances, economic and clinical effectiveness analyses will be required to determine their eligibility for coverage. These evaluations will help identify the most appropriate cost‑control measures for these drugs; for example, whether they should be subject to a Product Listing Agreement (PLA), be part of the prior authorization drug program, or be included in the step therapy program.
The following is an overview of the key areas our team of specialists will be closely monitoring over the coming months.
At Desjardins Insurance, we track developments in the pharmaceutical market and anticipate emerging trends to assess their impact on plans.
All medications, whether they be new drugs, biosimilars, or new indications, are rigorously evaluated by our Drug Evaluation Committee. This multidisciplinary committee, composed of pharmacists and specialists, reviews each drug from multiple angles: clinical effectiveness, safety, medical relevance, and financial impact on plans.
This structured approach allows us to design the most appropriate coverage strategies, ensuring responsible management while maintaining optimal access to necessary treatments.
We continually adapt our practices to maintain a balance between access to quality treatments and responsible cost management. Our goal remains the same: ensuring the plan’s financial sustainability while supporting the health and wellbeing of insureds.
At Desjardins Insurance, we track developments in the pharmaceutical market and anticipate emerging trends to assess their impact on plans.
All medications, whether they be new drugs, biosimilars, or new indications, are rigorously evaluated by our Drug Evaluation Committee. This multidisciplinary committee, composed of pharmacists and specialists, reviews each drug from multiple angles: clinical effectiveness, safety, medical relevance, and financial impact on plans.
This structured approach allows us to design the most appropriate coverage strategies, ensuring responsible management while maintaining optimal access to necessary treatments.
We continually adapt our practices to maintain a balance between access to quality treatments and responsible cost management. Our goal remains the same: ensuring the plan’s financial sustainability while supporting the health and wellbeing of insureds.